Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported its 2025 annual results, which met expectations, with revenue of 55.19 billion RMB, a slight decrease of 0.4% year-on-year, and a net profit of 19.15 billion RMB, down 7.1% year-on-year [6] - The medical beauty business is contributing a new growth curve, with the core product line and multiple series matrix continuously improving [6] - The company is focusing on shareholder returns, with a total dividend payout of approximately 1.29 billion RMB for the 2025 fiscal year [6] Financial Data and Profit Forecast - Revenue projections for 2026 are estimated at 60.45 billion RMB, with a year-on-year growth rate of 10% [5] - The net profit attributable to ordinary shareholders is forecasted to be 19.17 billion RMB in 2026, with a growth rate of 0% [5] - The earnings per share (EPS) for 2026 is projected to be 1.79 RMB, with a price-to-earnings (PE) ratio of 14.6 [5] Business Performance - The company's main product, "可复美," generated revenue of 44.7 billion RMB, accounting for 81% of total revenue, despite external shocks and industry competition [6] - The direct sales channel remained stable, with direct revenue of 41.4 billion RMB, representing 74.9% of total revenue [6] - The company is positioned in the collagen protein market, with both "可复美" and "可丽金" brands maintaining high growth rates [6]